A phase 2a safety run-in and preliminary efficacy study of liposomal gemcitabine (FF-10832) in combination with pembrolizumab in patients with advanced solid tumors

  • Corey J. Langer
  • , Brendan D. Curti
  • , Charles Michael Farber
  • , Catherine A. Wheeler
  • , David S. Wages
  • , Takeshi Matsumoto
  • , Susumu Shimoyama
  • , Mikinaga Mori
  • , Naoki Yamada
  • , Ruth Ann Subach
  • , Timothy Madden
  • , Mary Johansen
  • , Gary Maier
  • , Kin Cheung
  • , Marya F. Chaney
  • , Matt D. Galsky

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 2a safety run-in and preliminary efficacy study of liposomal gemcitabine (FF-10832) in combination with pembrolizumab in patients with advanced solid tumors'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science